Emerald Bioscience, Inc., formerly Nemus Bioscience, Inc., is a biopharmaceutical company. The Company is focused on the discovery, development and the commercialization of cannabinoid-based therapeutics through its partnership with the University of Mississippi (UM). The Company is focused primarily on the development of early-stage cannabinoid product candidates. The Company's product candidates include NB1111, NB2222 and NB3111. The Companyâ€™s NB1111, a prodrug of Tetrahydrocannabinol (THC), is the Company's lead ocular compound. Its NB2222 is a prototype ocular formulation of the Emerald Bioscience CBD analog. Its product candidate NB2222 has an eye drop emulsion for the potential treatment and management of several eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. The NB3111 product candidate is in research stage for the indication of Methicillin-resistant Staphylococcus aureus (MRSA).